Methallylescaline

Methallylescaline (3,5-dimethoxy-4-(2-methylallyloxy)phenethylamine), commonly abbreviated MAL, is a psychedelic phenethylamine and mescaline analog in which the 4-methoxy group of mescaline is replaced with a 4-(2-methylallyloxy) group — an allyloxy group with an additional methyl branch on the terminal carbon. It was synthesized by Alexander Shulgin as part of his extended mescaline analog program and documented in PiHKAL (1991).

MAL produces a psychedelic experience at doses of 40–75 mg lasting 8–12 hours, broadly within the mescaline-analog experiential family. Like escaline and allylescaline, it is characterized by visual richness, sensory enhancement, emotional warmth, and the relatively "soft" psychedelic quality associated with 5-HT2A-selective phenethylamines compared to the broader receptor profiles of tryptamines or the stimulant-heavy character of the 2C-I family. Community reports frequently describe MAL as having a particularly "organic" or "nature-oriented" quality — a characteristic that several users attribute specifically to the methylated allyloxy substituent, though this may reflect sample bias in who chooses to use unusual mescaline analogs.

MAL occupies a niche within the small community interested in Shulgin phenethylamines beyond the well-known 2C compounds. Its modest community experience base means that harm reduction information is largely extrapolated from mescaline analog pharmacology generally rather than compound-specific data. The compound's legal status is variable across jurisdictions — it is not always explicitly scheduled but is subject to phenethylamine analogue acts in many countries.